Gene · 10666
Papers4,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 4,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Is it time to switch to a formulation other than the live attenuated poliovirus vaccine to prevent poliomyelitis? | Front Public Health | 2023 | 38259741 | PubTator, text mining | PubMed |
| Treg in inborn errors of immunity: gaps, knowns and future perspectives. | Front Immunol | 2023 | 38259469 | PubTator, text mining | PubMed |
| Direct immunoactivation by chemotherapeutic drugs in cancer treatment. | Adv Ther (Weinh) | 2023 | 38249990 | PubTator, text mining | PubMed |
| Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases. | Front Immunol | 2023 | 38239346 | PubTator, text mining | PubMed |
| Current status and future perspective of natural killer cell therapy for cancer. | Med Rev (2021) | 2023 | 38235405 | PubTator, text mining | PubMed |
| Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. | J Cancer Metastasis Treat | 2023 | 38213954 | PubTator, text mining | PubMed |
| Non-Coding RNAs as Key Regulators in Lung Cancer. | Int J Mol Sci | 2023 | 38203731 | PubTator, text mining | PubMed |
| Soluble Forms of Immune Checkpoints and Their Ligands as Potential Biomarkers in the Diagnosis of Recurrent Pregnancy Loss-A Preliminary Study. | Int J Mol Sci | 2023 | 38203670 | PubTator, text mining | PubMed |
| The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival. | Int J Mol Sci | 2023 | 38203402 | PubTator, text mining | PubMed |
| Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma. | Cancers (Basel) | 2023 | 38201622 | PubTator, text mining | PubMed |
| NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells. | Cancers (Basel) | 2023 | 38201518 | PubTator, text mining | PubMed |
| Ovarian cancer treatment and natural killer cell-based immunotherapy. | Front Immunol | 2023 | 38187402 | PubTator, text mining | PubMed |
| Poliovirus receptor inhibition in breast cancer cells induces antitumor immunity via T cell activation. | Am J Cancer Res | 2023 | 38187056 | PubTator, text mining | PubMed |
| Canonical IRE1 function needed to sustain vigorous natural killer cell proliferation during viral infection. | iScience | 2023 | 38162021 | PubTator, text mining | PubMed |
| Single-cell RNA landscape of osteoimmune microenvironment in osteoporotic vertebral compression fracture and Kümmell's disease. | Front Cell Dev Biol | 2023 | 38161331 | PubTator, text mining | PubMed |
| Comprehensive analysis of mitophagy-related genes in NSCLC diagnosis and immune scenery: based on bulk and single-cell RNA sequencing data. | Front Immunol | 2023 | 38155968 | PubTator, text mining | PubMed |
| Corrigendum: Exploring the shared molecular mechanisms between systemic lupus erythematosus and primary Sjögren's syndrome based on integrated bioinformatics and single-cell RNA-seq analysis. | Front Immunol | 2023 | 38143754 | PubTator, text mining | PubMed |
| Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity. | Front Immunol | 2023 | 38143742 | PubTator, text mining | PubMed |
| Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments. | Int J Mol Sci | 2023 | 38139461 | PubTator, text mining | PubMed |
| The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. | Int J Mol Sci | 2023 | 38139373 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10666/papers?page=17